Name: UMIN ID:
Unique ID issued by UMIN | UMIN000023162 |
---|---|
Receipt number | R000026361 |
Scientific Title | A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study) |
Date of disclosure of the study information | 2016/09/15 |
Last modified on | 2022/01/20 10:47:53 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/07/14 11:15:26 | ||
2 | Update | 2016/09/14 10:22:05 | Anticipated trial start date |
|
3 | Update | 2016/10/12 10:15:42 | UMIN ID1 |
|
4 | Update | 2017/02/16 10:27:51 | Public title Acronym |
|
5 | Update | 2017/02/16 10:35:07 | Recruitment status |
|
6 | Update | 2017/07/24 09:49:36 | Anticipated trial start date |
|
7 | Update | 2018/01/15 15:10:09 | Institutions |
|
8 | Update | 2018/08/23 17:47:05 | Acronym |
|
9 | Update | 2019/07/18 20:13:07 | Recruitment status Date of IRB Last follow-up date |
|
10 | Update | 2019/09/05 16:14:42 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
11 | Update | 2019/09/05 16:15:07 | Number of participants that the trial has enrolled |
|
12 | Update | 2020/01/21 13:42:52 | Division name |
|
13 | Update | 2020/02/05 17:23:38 | Anticipated trial start date Last follow-up date |
|
14 | Update | 2021/06/16 15:20:19 | Last name of contact person Last name of contact person Organization Homepage URL Name of person sending information Name of person sending information Organization Division name Institute |
|
15 | Update | 2022/01/20 10:47:53 | Email |